Immunotherapy Combo Trial for Advanced Solid Tumors Doses First Patient – Immuno-Oncology News
Immuno-Oncology News |
Immunotherapy Combo Trial for Advanced Solid Tumors Doses First Patient
Immuno-Oncology News A Phase 1 trial assessing a combination of the immune checkpoint inhibitor Yervoy (ipilimumab) and Transgene's oncolytic virus Pexa-Vec as a treatment for multiple advanced solid tumors has dosed its first patient at the Léon Bérard Cancer Center in … |
